It has been known for so long that optimal glycemic control in type 1 diabetes can decrease the risk of micro and macrovascular complications, but why is the risk still high despite intensive glycemic control?
Read More »Rotavirus Vaccination A Practical Measure to Prevent Type 1 Diabetes
If environmental factors such as enteroviruses can trigger beta-cell autoimmunity, then is it possible that a vaccine can reduce the likelihood of developing type 1 diabetes?
Read More »The Risks of Cognitive Impairment in Our Elderly Patients with Diabetes
How does diabetes affect the risk of developing late-life mild cognitive impairment or dementia?
Read More »The CARMELINA Trial: Linagliptin’s Cardiovascular Effects for Type 2 Diabetes with High Cardiorenal Risk — ADA 2019
The CARMELINA trial demonstrated noninferiority of linagliptin compared with placebo in CV events in high risk people with type 2 diabetes.
Read More »Development of Heart Disease in Young Adults with Type 1 Diabetes — ADA 2019
Could older recommendations of maintaining a blood pressure of 140/90 mmHg be misleading in younger adults with type 1 diabetes for cardiovascular risk reduction?
Read More »EMPA-REG OUTCOME Trial: Reducing Cardiovascular Risk For T2D Patients
The results of EMPA-REG OUTCOME Trial assess the role of empagliflozin in patients with type 2 diabetes and atherosclerotic cardiovascular disease.
Read More »Liraglutide for Youth with Type 2 Diabetes
The lack of studies for children and adolescents with type 2 diabetes has led to an absence of approval of new drugs for this patient population. This study reports findings of Liraglutide for youth.
Read More »The Association Between Cardiac Autonomic Dysfunction and Impaired Myocardial Blood Flow Regulation — ADA
Myocardial flow reserve plays a significant role as a predictor of cardiac death in patients with diabetes.
Read More »Oral Semaglutide vs Subcutaneous GLP-1RAs — ADA 2019
New research findings on oral semaglutide vs subcutaneous liraglutide.
Read More »The Incidence of Type 2 Diabetes in Patients Receiving Vitamin D Supplementation — ADA 2019
The role of 25-hydroxyvitamin D in the progression of type 2 diabetes continues to be explored after a recent study observes diabetes incidence in high risk patients receiving vitamin supplementation.
Read More »